Gonalef® (Follitropin alfa) + Purified pituitary gonadotropin (Fertinorm-P®)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Infertility
Conditions
Infertility, Ovulation Induction
Trial Timeline
Feb 1, 2007 → Dec 1, 2007
NCT ID
NCT01185782About Gonalef® (Follitropin alfa) + Purified pituitary gonadotropin (Fertinorm-P®)
Gonalef® (Follitropin alfa) + Purified pituitary gonadotropin (Fertinorm-P®) is a phase 3 stage product being developed by Merck for Infertility. The current trial status is completed. This product is registered under clinical trial identifier NCT01185782. Target conditions include Infertility, Ovulation Induction.
What happened to similar drugs?
11 of 20 similar drugs in Infertility were approved
Approved (11) Terminated (4) Active (9)
🔄GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + ProgesteroneSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01185782 | Phase 3 | Completed |
Competing Products
20 competing products in Infertility